SCHEMBL12092176

SCHEMBL12092176

COC(=O)COCCOS(C)(=O)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.43
USP2 O75604 2/20 0.43
ALDH1A1 P00352 2/20 0.43
LMNA P02545 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MMP9 P14780 1/20 0.43
ALOX15 P16050 1/20 0.43
CA12 O43570 2/20 0.35
CA14 Q9ULX7 2/20 0.35
HSD17B10 Q99714 1/20 0.33
MGAM O43451 1/20 0.33
GAA P10253 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33
FNTA P49354 1/20 0.32
FNTB P49356 1/20 0.32
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
MEN1 O00255 1/20 0.30
CYP1A2 P05177 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24675254 0.84 TSHR (0.50) TSHRUSP2ALDH1A1LMNAKDM4E
SCHEMBL6463788 0.82 TSHR (0.50) TSHRALDH1A1LMNAKDM4ECA12
SCHEMBL12092174 0.82 TSHR (0.44) TSHRUSP2ALDH1A1LMNAKDM4E
SCHEMBL3441325 0.81 TSHR (0.43) TSHRUSP2ALDH1A1LMNAKDM4E
SCHEMBL7648165 0.80 TSHR (0.48) TSHRLMNAKDM4ECA12CA14
SCHEMBL16827028 0.79 KDM4E (0.39) TSHRUSP2ALDH1A1LMNAKDM4E
SCHEMBL21070902 0.79 ALDH1A1 (0.39) TSHRUSP2ALDH1A1LMNAKDM4E
SCHEMBL21069949 0.79 ALDH1A1 (0.39) TSHRUSP2ALDH1A1LMNAKDM4E
SCHEMBL18105871 0.79 ALDH1A1 (0.39) TSHRUSP2ALDH1A1LMNAKDM4E
SCHEMBL19434510 0.79 ALDH1A1 (0.39) TSHRUSP2ALDH1A1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952147-B2 Conjugates, preparation thereof, and therapeutic use thereof SANOFI (FR) 2015-02-10 US disclosed
US-20120225089-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225089-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF ERG28, CARS1, FOLH1 TSHR 4077/4885USP2 3339/4885ALDH1A1 1912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.